loader
Please Wait
Applying Filters...

Annual Sales of Nilotinib reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 4,817Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Tasigna

PharmaCompass

01

Brand Name : Tasigna

Nilotinib

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,958

2019 Revenue in Millions : 1,880

Growth (%) : 4

blank

02

Brand Name : Tasigna

Nilotinib

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 2,060

2020 Revenue in Millions : 1,958

Growth (%) : 5

blank

03

Brand Name : Tasigna

Nilotinib

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 1,923

2021 Revenue in Millions : 2,060

Growth (%) : -7

blank

04

Brand Name : Tasigna

Nilotinib

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,848

2022 Revenue in Millions : 1,923

Growth (%) : -4

blank

05

Brand Name : Tasigna

Nilotinib Hydrochloride

arrow
BioProcess International
Not Confirmed

06

Brand Name : Tasigna

Nilotinib Hydrochloride

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib Hydrochloride

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 1,529

2014 Revenue in Millions : 1,632

Growth (%) : 7%

blank

07

Brand Name : Tasigna

Nilotinib Hydrochloride

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib Hydrochloride

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,739

2015 Revenue in Millions : 1,632

Growth (%) : 7

blank

08

Brand Name : Tasigna

Nilotinib Hydrochloride

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib Hydrochloride

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,841

2016 Revenue in Millions : 1,739

Growth (%) : 6

blank

09

Brand Name : Tasigna

Nilotinib Hydrochloride

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib Hydrochloride

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,874

2017 Revenue in Millions : 1,841

Growth (%) : 2%

blank

10

Brand Name : Tasigna

Nilotinib

arrow
BioProcess International
Not Confirmed

Brand Name : Tasigna

arrow
BioProcess International
Not Confirmed

Nilotinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,880

2018 Revenue in Millions : 1,874

Growth (%) : 0

blank